Apnimed (NASDAQ:APMD – Get Free Report) issued its earnings results on Monday. The company reported ($1.05) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $2.48 million for the quarter.
Apnimed Stock Down 3.8%
NASDAQ:APMD opened at $16.28 on Tuesday. The stock has a 50 day moving average of $20.29. Apnimed has a 12 month low of $13.88 and a 12 month high of $35.29.
Hedge Funds Weigh In On Apnimed
An institutional investor recently bought a new stake in Apnimed stock. Integral Health Asset Management LLC acquired a new position in Apnimed, Inc. (NASDAQ:APMD – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 225,000 shares of the company’s stock, valued at approximately $4,930,000. Integral Health Asset Management LLC owned 0.54% of Apnimed at the end of the most recent reporting period.
Wall Street Analysts Forecast Growth
APMD has been the topic of a number of recent analyst reports. Cantor Fitzgerald assumed coverage on shares of Apnimed in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target on the stock. Weiss Ratings assumed coverage on shares of Apnimed in a report on Tuesday, October 27th. They issued a “sell (e-)” rating for the company. Bank of America assumed coverage on Apnimed in a research report on Tuesday, August 25th. They issued a “buy” rating and a $41.00 price objective on the stock. Lifesci Capital began coverage on Apnimed in a research note on Tuesday, August 25th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Evercore started coverage on Apnimed in a report on Tuesday, August 25th. They issued an “outperform” rating for the company. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Apnimed currently has an average rating of “Moderate Buy” and a consensus target price of $50.33.
View Our Latest Analysis on Apnimed
Apnimed Company Profile
Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.
Read More
- Five stocks we like better than Apnimed
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
